**Technology Advisory Committee HST Interests Register**

**Topic: [ID1473] Onasemnogene abeparvovec for treating spinal muscular atrophy**

**Publication Date: 7 July 2021**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| Francis Pang | Committee Member | Financial | Francis is a former employee and shareholder of one of the comparator companies: Biogen so will not be participating for this particular HST topic |  | 24/09/2020 |  | It was agreed that his declaration would prevent Francis from participating in this section of the meeting |
| Adnan Manzur | Clinical Expert | Direct personal | He has done consulting work for Biogen: “SMA Expert questionnaire and advisory board” which took place in July 2017. |  | 08/10/2020 |  | It was agreed that his declaration would not prevent Adnan from participating in this section of the meeting |
| Volker Straub | Clinical Expert | Financial  | He received speaker honoraria from Sanofi Genzyme. He has or is currently on advisory boards for Audentes Therapeutics, AveXis (Novartis Gene Therapies), Biogen, Bristol-Myer Squibb, Exonics Therapeutics, Italfarmaco S.p.A., Pfizer, Roche, Sanofi Genzyme, Sarepta Therapeutics, Summit Therapeutics, Tivorsan, UCB, and Wave Therapeutics. He also had research collaborations with Ultragenyx and Sanofi Genzyme. |  | 08/10/2020 |  | It was agreed that his declaration would not prevent Volker from participating in this section of the meeting |